Literature DB >> 15948444

Metal-on-metal: articulations for the new millennium.

Lawrence D Dorr1, William T Long.   

Abstract

Implants with metal-on-metal articulations (Metasul, Sulzer Medica, Winterthur, Switzerland [now Zimmer, Warsaw, IN]) have been used in nearly 300,000 total hip replacements. In three different clinical studies, clinical success has been demonstrated using this implant as measured by Harris hip scores, patient self-assessment, and assessment of mechanical complications. Of a study group of 924 patients who received this implant, the only reported complications were mechanical, incldding two cup loosenings (0.2%) and 36 dislocations (4.0%). In a randomized study, clinical resultsfor the group that received implants with metal-on-metal articulation were comparable to those of the ceramic-on-polyethylene (control) group. Reports assessing retrieved implants with metal-on-metal articulation demonstrate low annual linear wear rates and no consequences of elevated cobalt ion levels at follow-up from 4 years to 26 years. In light of these data, the continued ise of metal-on-metal articulations is recommended for any patient who does not have compromised renal function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15948444

Source DB:  PubMed          Journal:  Instr Course Lect        ISSN: 0065-6895


  3 in total

1.  Alumina-on-alumina hip arthroplasty in patients younger than 30 years old.

Authors:  R Nizard; D Pourreyron; A Raould; D Hannouche; L Sedel
Journal:  Clin Orthop Relat Res       Date:  2008-01-10       Impact factor: 4.176

2.  Astaxanthin mitigates cobalt cytotoxicity in the MG-63 cells by modulating the oxidative stress.

Authors:  Dahe Li; Wenwen Tong; Denghui Liu; Yuming Zou; Chen Zhang; Weidong Xu
Journal:  BMC Pharmacol Toxicol       Date:  2017-07-24       Impact factor: 2.483

3.  Mean 5-year clinical and radiographic outcomes of cementless total hip arthroplasty in patients under the age of 30.

Authors:  Jeremy M Gililland; Lucas A Anderson; Jill Erickson; Christopher E Pelt; Christopher L Peters
Journal:  Biomed Res Int       Date:  2013-06-24       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.